Market Place
Sourcing Support
Reata culls bardoxolone, ending decade of R&D on troubled kidney disease drug
11 May 2023 //
ENDPTS
Reata, Kyowa Kirin ax bardoxolone, ending 13-year saga
10 May 2023 //
FIERCE BIOTECH
Reata Pharma to Report 2nd Quarter 2022 Financial Results
01 Aug 2022 //
BUSINESSWIRE
Reata slips as FDA rejects kidney disease therapy
26 Feb 2022 //
SEEKING ALPHA
FDA slams Reata`s kidney drug as ineffective ahead of adcomm meeting
06 Dec 2021 //
ENDPTS
Reata , Inc. Submits NDA for Company’s Lead Program: Bardoxolone
01 Mar 2021 //
GLOBENEWSWIRE
Reata Announces +VE Results From 2y of the Pivotal Ph3 Study of Bardoxolone
09 Nov 2020 //
PRESSRELEASE
Reata Announces Initiation Investigator-Sponsored Study Evaluating Bardoxolone
27 Jul 2020 //
GLOBENEWSWIRE
Two preclinical biotechs riding the IPO wave this week look to raise $466M-plus
11 Jun 2020 //
ENDPTS
Reata`s bardoxolone offers promise in patients with rare kidney disorder
12 Nov 2019 //
ENDPTS
Reata`s kidney med bardoxolone delivers in phase 3, teeing up FDA filing
11 Nov 2019 //
FIERCE BIOTECH
Reata’s bardoxolone hits goals in phase 2 kidney disease trial
25 Sep 2018 //
FIERCE BIOTECH
Ph2 Trial Data Show Bardoxolone’s Potential to Reverse Kidney Damage
29 Jul 2018 //
ALPORTSYNDROMESEWS
Reata +ve Ph2 Data for Bardoxolone Methyl in CKD Caused by Alport Syndrome
23 Jul 2018 //
PRESS RELEASE
Reata Announces, Kyowa Hakko Kirin Initiated AYAME, Ph3 of Bardoxolone Methyl
04 Jun 2018 //
PRESS RELEASE
Reata Announces Orphan Drug Desig. From the EU Commission Bardoxolone Methyl
31 May 2018 //
PRESS RELEASE
Bardoxolone Methyl Improved Kidney Function Patients Phase 2 Phoenix Study
25 May 2018 //
PRESS RELEASE
Reata Update on the Ph2 Portion of the CARDINAL Study of Bardoxolone Methyl
11 Apr 2018 //
PRESS RELEASE
Reata Announces Improvements in Kidney Function With Bardoxolone Methyl
12 Feb 2018 //
PRESS RELEASE
Reata Efficacy Data From the Beacon Study of Bardoxolone in Diabetic CKD
18 Jan 2018 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.